Cogent Biosciences (COGT) Stock Forecast & Price Target $5.99 -0.49 (-7.56%) Closing price 03/31/2025 04:00 PM EasternExtended Trading$6.26 +0.27 (+4.49%) As of 03/31/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cogent Biosciences - Analysts' Recommendations and Stock Price Forecast (2025) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 8 Analyst RatingsSell0Hold3Buy5 Based on 8 Wall Street analysts who have issued ratings for Cogent Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 3 have given a hold rating, 4 have given a buy rating, and 1 has given a strong buy rating for COGT. Consensus Price Target $14.43140.88% Upside According to the 8 analysts' twelve-month price targets for Cogent Biosciences, the average price target is $14.43. The highest price target for COGT is $21.00, while the lowest price target for COGT is $8.00. The average price target represents a forecasted upside of 140.88% from the current price of $5.99. Get the Latest News and Ratings for COGT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cogent Biosciences and its competitors. Enter your email to sign up for newsletter Sign Up COGT Analyst Ratings Over TimeTypeCurrent Forecast4/1/24 to 4/1/251 Month Ago3/2/24 to 3/2/253 Months Ago1/2/24 to 1/1/251 Year Ago4/2/23 to 4/1/24Strong Buy1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy4 Buy rating(s)3 Buy rating(s)4 Buy rating(s)5 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)3 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$14.43$14.00$14.83$13.67Forecasted Upside140.88% Upside85.92% Upside90.17% Upside98.07% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy Remove Ads COGT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History COGT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Cogent Biosciences Stock vs. The CompetitionTypeCogent BiosciencesMedical CompaniesS&P 500Consensus Rating Score 2.75 2.82 2.54Consensus RatingModerate BuyModerate BuyModerate BuyPredicted Upside140.88% Upside19,270.47% Upside19.03% UpsideNews Sentiment RatingPositive NewsSee Recent COGT NewsPositive NewsPositive News Remove Ads Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails3/7/2025Piper Sandler2 of 5 starsA. BratzelSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025Scotiabank5 of 5 starsLouise ChenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$17.00+129.42%2/27/2025Robert W. Baird2 of 5 starsJoel BeattySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetNeutral ➝ Neutral$10.00 ➝ $8.00+19.23%2/26/2025Needham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. FadiaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold2/25/2025WedbushSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingNeutral$11.00+56.47%1/14/2025HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingRobert BurnsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetBuy ➝ Buy$17.00 ➝ $14.00+84.94%11/14/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$19.00 ➝ $21.00+112.55%9/24/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$13.00 ➝ $15.00+39.28%2/22/2024Leerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingA. BerensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperformAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:19 AM ET. COGT Forecast - Frequently Asked Questions What is Cogent Biosciences' forecast for 2025? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Cogent Biosciences is $14.43, with a high forecast of $21.00 and a low forecast of $8.00. Should I buy or sell Cogent Biosciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last twelve months. There are currently 3 hold ratings, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COGT shares. Does Cogent Biosciences's stock price have much upside? According to analysts, Cogent Biosciences's stock has a predicted upside of 140.88% based on their 12-month stock forecasts. Has Cogent Biosciences been upgraded by Wall Street analysts recently? Over the previous 90 days, Cogent Biosciences's stock had 1 upgrade by analysts. What analysts cover Cogent Biosciences? Cogent Biosciences has been rated by research analysts at HC Wainwright, Needham & Company LLC, Piper Sandler, Robert W. Baird, Scotiabank, and Wedbush in the past 90 days. Do Wall Street analysts like Cogent Biosciences more than its competitors? Analysts like Cogent Biosciences less than other "medical" companies. The consensus rating score for Cogent Biosciences is 2.75 while the average consensus rating score for "medical" companies is 2.82. Learn more on how COGT compares to other companies. Stock Forecasts and Research Tools Related Companies VKTX Stock Forecast HCM Stock Forecast AMRX Stock Forecast IBRX Stock Forecast XENE Stock Forecast MLTX Stock Forecast BHVN Stock Forecast BHC Stock Forecast TWST Stock Forecast NAMS Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:COGT) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COGT Stock Free COGT Stock Alerts